Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database
Identifieur interne : 000458 ( France/Analysis ); précédent : 000457; suivant : 000459Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database
Auteurs : QIAN SHI [États-Unis] ; Thierry Andre [France] ; Axel Grothey [États-Unis] ; Greg Yothers [États-Unis] ; Stanley R. Hamilton [États-Unis] ; Brian M. Bot [États-Unis] ; Daniel G. Haller [États-Unis] ; Eric Van Cutsem [Belgique] ; Chris Twelves [Royaume-Uni] ; Jacqueline K. Benedetti [États-Unis] ; Michael J. O'Connell [États-Unis] ; Daniel J. Sargent [États-Unis]Source :
- Journal of clinical oncology [ 0732-183X ] ; 2013.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Base de données.
English descriptors
- KwdEn :
Abstract
Purpose With improved patient care, better diagnosis, and more treatment options after tumor recurrence, outcomes after fluorouracil (FU) -based treatment are expected to have improved over time in early-stage colon cancer. Data from 18,449 patients enrolled onto 21 phase III trials conducted from 1978 to 2002 were evaluated for potential differences in time to recurrence (TTR), time from recurrence to death (TRD), and overall survival (OS) with regard to FU-based adjuvant regimens. Methods Trials were predefined as old versus newer era using initial accrual before or after 1995. Outcomes were compared between patients enrolled onto old- or newer-era trials, stratified by stage. Results Within the first 3 years, recurrence rates were lower in newer- versus old-era trials for patients with stage II disease, with no differences among those with stage III disease. Both TRD and OS were significantly longer in newer-era trials overall and within each stage. The lymph node (LN) ratio (ie, number of positive nodes divided by total nodes harvested) in those with stage III disease declined over time. TTR improved slightly, with larger number of LNs examined in both stages. Conclusion Improved TRD in newer trials supports the premise that more aggressive intervention (oxaliplatin-and irinotecan-based chemotherapy and/or surgery for recurrent disease) improves OS for patients previously treated in the adjuvant setting. Lower recurrence rates with identical treatments in those with stage II disease enrolled onto newer-era trials reflect stage migration over time, calling into question historical data related to the benefit of FU-based adjuvant therapy in such patients.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001975
- to stream PascalFrancis, to step Curation: 003006
- to stream PascalFrancis, to step Checkpoint: 001E85
- to stream Main, to step Merge: 007706
- to stream Main, to step Curation: 007253
- to stream Main, to step Exploration: 007253
- to stream France, to step Extraction: 000458
Links to Exploration step
Pascal:13-0323552Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database</title><author><name sortKey="Qian Shi" sort="Qian Shi" uniqKey="Qian Shi" last="Qian Shi">QIAN SHI</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>North Central Cancer Treatment Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="Andre">Thierry Andre</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Hôpital Saint Antoine</s1><s2>Paris</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Grothey, Axel" sort="Grothey, Axel" uniqKey="Grothey A" first="Axel" last="Grothey">Axel Grothey</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>North Central Cancer Treatment Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Yothers, Greg" sort="Yothers, Greg" uniqKey="Yothers G" first="Greg" last="Yothers">Greg Yothers</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>National Surgical Adjuvant Breast and Bowel Project</s1><s2>Pittsburgh</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Pittsburgh</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Hamilton, Stanley R" sort="Hamilton, Stanley R" uniqKey="Hamilton S" first="Stanley R." last="Hamilton">Stanley R. Hamilton</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>University of Texas MD Anderson Cancer Center</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Texas MD Anderson Cancer Center</wicri:noRegion></affiliation></author><author><name sortKey="Bot, Brian M" sort="Bot, Brian M" uniqKey="Bot B" first="Brian M." last="Bot">Brian M. Bot</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>North Central Cancer Treatment Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Southwest Oncology Group Statistical Center</s1><s2>Seattle, WA</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Southwest Oncology Group Statistical Center</wicri:noRegion></affiliation></author><author><name sortKey="Haller, Daniel G" sort="Haller, Daniel G" uniqKey="Haller D" first="Daniel G." last="Haller">Daniel G. Haller</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Abramson Cancer Center, University of Pennsylvania</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Philadelphia, PA</wicri:noRegion></affiliation></author><author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>University Hospital Gasthuisberg</s1><s2>Gasthuisberg</s2><s3>BEL</s3><sZ>8 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>University Hospital Gasthuisberg</wicri:noRegion></affiliation></author><author><name sortKey="Twelves, Chris" sort="Twelves, Chris" uniqKey="Twelves C" first="Chris" last="Twelves">Chris Twelves</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>St James's University Hospital</s1><s2>Leeds</s2><s3>GBR</s3><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>St James's University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Benedetti, Jacqueline K" sort="Benedetti, Jacqueline K" uniqKey="Benedetti J" first="Jacqueline K." last="Benedetti">Jacqueline K. Benedetti</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Southwest Oncology Group Statistical Center</s1><s2>Seattle, WA</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Southwest Oncology Group Statistical Center</wicri:noRegion></affiliation></author><author><name sortKey="O Connell, Michael J" sort="O Connell, Michael J" uniqKey="O Connell M" first="Michael J." last="O'Connell">Michael J. O'Connell</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>National Surgical Adjuvant Breast and Bowel Project</s1><s2>Pittsburgh</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Pittsburgh</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Sargent, Daniel J" sort="Sargent, Daniel J" uniqKey="Sargent D" first="Daniel J." last="Sargent">Daniel J. Sargent</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>North Central Cancer Treatment Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">13-0323552</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 13-0323552 INIST</idno><idno type="RBID">Pascal:13-0323552</idno><idno type="wicri:Area/PascalFrancis/Corpus">001975</idno><idno type="wicri:Area/PascalFrancis/Curation">003006</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001E85</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001E85</idno><idno type="wicri:doubleKey">0732-183X:2013:Qian Shi:comparison:of:outcomes</idno><idno type="wicri:Area/Main/Merge">007706</idno><idno type="wicri:Area/Main/Curation">007253</idno><idno type="wicri:Area/Main/Exploration">007253</idno><idno type="wicri:Area/France/Extraction">000458</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database</title><author><name sortKey="Qian Shi" sort="Qian Shi" uniqKey="Qian Shi" last="Qian Shi">QIAN SHI</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>North Central Cancer Treatment Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="Andre">Thierry Andre</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Hôpital Saint Antoine</s1><s2>Paris</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Grothey, Axel" sort="Grothey, Axel" uniqKey="Grothey A" first="Axel" last="Grothey">Axel Grothey</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>North Central Cancer Treatment Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author><author><name sortKey="Yothers, Greg" sort="Yothers, Greg" uniqKey="Yothers G" first="Greg" last="Yothers">Greg Yothers</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>National Surgical Adjuvant Breast and Bowel Project</s1><s2>Pittsburgh</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Pittsburgh</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Hamilton, Stanley R" sort="Hamilton, Stanley R" uniqKey="Hamilton S" first="Stanley R." last="Hamilton">Stanley R. Hamilton</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>University of Texas MD Anderson Cancer Center</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Texas MD Anderson Cancer Center</wicri:noRegion></affiliation></author><author><name sortKey="Bot, Brian M" sort="Bot, Brian M" uniqKey="Bot B" first="Brian M." last="Bot">Brian M. Bot</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>North Central Cancer Treatment Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Southwest Oncology Group Statistical Center</s1><s2>Seattle, WA</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Southwest Oncology Group Statistical Center</wicri:noRegion></affiliation></author><author><name sortKey="Haller, Daniel G" sort="Haller, Daniel G" uniqKey="Haller D" first="Daniel G." last="Haller">Daniel G. Haller</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Abramson Cancer Center, University of Pennsylvania</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Philadelphia, PA</wicri:noRegion></affiliation></author><author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>University Hospital Gasthuisberg</s1><s2>Gasthuisberg</s2><s3>BEL</s3><sZ>8 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>University Hospital Gasthuisberg</wicri:noRegion></affiliation></author><author><name sortKey="Twelves, Chris" sort="Twelves, Chris" uniqKey="Twelves C" first="Chris" last="Twelves">Chris Twelves</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>St James's University Hospital</s1><s2>Leeds</s2><s3>GBR</s3><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>St James's University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Benedetti, Jacqueline K" sort="Benedetti, Jacqueline K" uniqKey="Benedetti J" first="Jacqueline K." last="Benedetti">Jacqueline K. Benedetti</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Southwest Oncology Group Statistical Center</s1><s2>Seattle, WA</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Southwest Oncology Group Statistical Center</wicri:noRegion></affiliation></author><author><name sortKey="O Connell, Michael J" sort="O Connell, Michael J" uniqKey="O Connell M" first="Michael J." last="O'Connell">Michael J. O'Connell</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>National Surgical Adjuvant Breast and Bowel Project</s1><s2>Pittsburgh</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Pittsburgh</settlement><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Sargent, Daniel J" sort="Sargent, Daniel J" uniqKey="Sargent D" first="Daniel J." last="Sargent">Daniel J. Sargent</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>North Central Cancer Treatment Group, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant treatment</term><term>Advanced stage</term><term>Antineoplastic agent</term><term>Cancerology</term><term>Cell migration</term><term>Clinical stage</term><term>Colon cancer</term><term>Comparative study</term><term>Database</term><term>Early stage</term><term>Evolution</term><term>Fluorouracil</term><term>Locally advanced stage</term><term>Prognosis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Fluorouracil</term><term>Etude comparative</term><term>Pronostic</term><term>Cancer du côlon</term><term>Evolution</term><term>Traitement adjuvant</term><term>Stade précoce</term><term>Stade avancé</term><term>Stade clinique</term><term>Migration cellulaire</term><term>Base de données</term><term>Cancérologie</term><term>Anticancéreux</term><term>Stade localement avancé</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Base de données</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose With improved patient care, better diagnosis, and more treatment options after tumor recurrence, outcomes after fluorouracil (FU) -based treatment are expected to have improved over time in early-stage colon cancer. Data from 18,449 patients enrolled onto 21 phase III trials conducted from 1978 to 2002 were evaluated for potential differences in time to recurrence (TTR), time from recurrence to death (TRD), and overall survival (OS) with regard to FU-based adjuvant regimens. Methods Trials were predefined as old versus newer era using initial accrual before or after 1995. Outcomes were compared between patients enrolled onto old- or newer-era trials, stratified by stage. Results Within the first 3 years, recurrence rates were lower in newer- versus old-era trials for patients with stage II disease, with no differences among those with stage III disease. Both TRD and OS were significantly longer in newer-era trials overall and within each stage. The lymph node (LN) ratio (ie, number of positive nodes divided by total nodes harvested) in those with stage III disease declined over time. TTR improved slightly, with larger number of LNs examined in both stages. Conclusion Improved TRD in newer trials supports the premise that more aggressive intervention (oxaliplatin-and irinotecan-based chemotherapy and/or surgery for recurrent disease) improves OS for patients previously treated in the adjuvant setting. Lower recurrence rates with identical treatments in those with stage II disease enrolled onto newer-era trials reflect stage migration over time, calling into question historical data related to the benefit of FU-based adjuvant therapy in such patients.</div></front></TEI><affiliations><list><country><li>Belgique</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Pennsylvanie</li><li>Île-de-France</li></region><settlement><li>Paris</li><li>Pittsburgh</li></settlement></list><tree><country name="États-Unis"><noRegion><name sortKey="Qian Shi" sort="Qian Shi" uniqKey="Qian Shi" last="Qian Shi">QIAN SHI</name></noRegion><name sortKey="Benedetti, Jacqueline K" sort="Benedetti, Jacqueline K" uniqKey="Benedetti J" first="Jacqueline K." last="Benedetti">Jacqueline K. Benedetti</name><name sortKey="Bot, Brian M" sort="Bot, Brian M" uniqKey="Bot B" first="Brian M." last="Bot">Brian M. Bot</name><name sortKey="Bot, Brian M" sort="Bot, Brian M" uniqKey="Bot B" first="Brian M." last="Bot">Brian M. Bot</name><name sortKey="Grothey, Axel" sort="Grothey, Axel" uniqKey="Grothey A" first="Axel" last="Grothey">Axel Grothey</name><name sortKey="Haller, Daniel G" sort="Haller, Daniel G" uniqKey="Haller D" first="Daniel G." last="Haller">Daniel G. Haller</name><name sortKey="Hamilton, Stanley R" sort="Hamilton, Stanley R" uniqKey="Hamilton S" first="Stanley R." last="Hamilton">Stanley R. Hamilton</name><name sortKey="O Connell, Michael J" sort="O Connell, Michael J" uniqKey="O Connell M" first="Michael J." last="O'Connell">Michael J. O'Connell</name><name sortKey="Sargent, Daniel J" sort="Sargent, Daniel J" uniqKey="Sargent D" first="Daniel J." last="Sargent">Daniel J. Sargent</name><name sortKey="Yothers, Greg" sort="Yothers, Greg" uniqKey="Yothers G" first="Greg" last="Yothers">Greg Yothers</name></country><country name="France"><region name="Île-de-France"><name sortKey="Andre, Thierry" sort="Andre, Thierry" uniqKey="Andre T" first="Thierry" last="Andre">Thierry Andre</name></region></country><country name="Belgique"><noRegion><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Twelves, Chris" sort="Twelves, Chris" uniqKey="Twelves C" first="Chris" last="Twelves">Chris Twelves</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000458 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000458 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= France
|étape= Analysis
|type= RBID
|clé= Pascal:13-0323552
|texte= Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database
}}
| This area was generated with Dilib version V0.6.38. |  |